SABCS 2024丨乳腺癌领域年终盛典将至，重磅研究汇总！

点击蓝字，关注我们

LB1-01: Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.

讲者：Robert Hills, University of Oxford, Oxford, United Kingdom

LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer.

讲者：Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.

讲者：Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany

LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.

讲者：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

LB1-05: ROSC (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.

讲者：Sherko Kuemmel, German Medical Institute, Limassol, Germany

LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).

讲者：Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.

讲者：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial.

讲者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial.

讲者：徐兵河（中国医学科学院肿瘤医院）

GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial.

讲者：李俊杰（复旦大学附属肿瘤医院）

GS1-06: PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.

讲者：Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin

GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study.

讲者：Matteo Lambertini, University of Genova, Genova, Italy

GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.

讲者：Judy Garber, Dana-Farber Cancer Institute, Boston, Massachusetts

RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance).

讲者：Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts

RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

讲者：Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy

RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).

讲者：Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands

RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer.

讲者：Azka Ali, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois

RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.

讲者：Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois

RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.

讲者：Katie Johansen Taber, Myriad Genetics, San Francisco, California

RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.

讲者：Bojana Stefanovska, UT Health Science Center, San Antonio, Texas

GS2-01: Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

讲者：Icro Meattini, University of Florence, Florence, Italy

GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial

讲者：Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina

GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.

讲者：Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland

GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).

讲者：Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina

GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).

讲者：Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts

GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.

讲者：Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany

GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.

讲者：Hongchao Pan, University of Oxford, Oxford, United Kingdom

GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer.

讲者：Mikael Eriksson, Karolinska Institutet, Solna, Sweden

GS2-11: APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.

讲者：Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York

RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.

讲者：Judy Boughey, Mayo Clinic, Rochester, Minnesota

RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.

讲者：Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH

RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).

讲者：Steffi Hartmann, University of Rostock, Rostock, Germany

RF2-04: Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO).

讲者：Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium

RF2-05: Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.

讲者：Demet Özcan, Aarhus University Hospital, Aarhus, Denmark

RF2-06: A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.

讲者：Luke Peppone, University of Rochester Medical Center, Rochester, New York

GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.

讲者：Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom

GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.

讲者：Nan Chen, University of Chicago Medicine, Chicago, Illinois

GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER2- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.

讲者：Sherko Kuemmel, German Medical Institute, Berlin, Germany

GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.

讲者：Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania

GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.

讲者：邵志敏（复旦大学附属肿瘤医院）

GS3-08: In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.

讲者：Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.

讲者：Enrico Moiso, Memorial Sloan Kettering Cancer Center, New York, New York

GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.

讲者：Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina

RF3-01: TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.

讲者：Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

RF3-02: Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.

讲者：Maria Vittoria Dieci, University of Padua, Padua, Italy

RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.

讲者：Olivier Trédan, Centre Lèon Bèrard, Lyon, France

RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.

讲者：Vicente Valero, MD Anderson Cancer Center, Houston, Texas

RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP).

讲者：Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

RF3-06: Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial

讲者：Kimberly Corbin, Mayo Clinic, Rochester, Minnesota

RF3-07: ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.

讲者：Daniel Rea, University of Birmingham, Birmingham, United Kingdom

Session 1: New Insights into Immune Biomarkers（免疫生物标志物的新见解）

地点：Room 221ABC

主持人：David Rimm, Yale University

Session 3: Highlights on Novel Therapeutics（新型治疗亮点）

地点：Stars at Night 1-2

主持人：Sara Tolaney, Dana-Farber Cancer Institute

Session 4: Prediction of Chemotherapy Response（化疗疗效预测）

地点：Stars at Night 3-4

主持人：Sherene Loi, Peter Macallum Cancer Centre

Session 5: The Heart of the Matter - Improving Adverse Effects（核心问题-改善不良反应）

地点：Hemisfair Ballroom 3

主持人：Anne Blaes, Masonic Cancer Center University of Minnesota

Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations（靶向ER和PI3K通路：新型药物和组合）

地点：Hemisfair Ballroom 1-2

主持人：Shom Goel, Peter MacCallum Cancer Centre

Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers（转移性乳腺癌患者的个体化CDK 4/6抑制剂治疗：生存期、生活质量和生物标志物）

地点：Hemisfair Ballroom 1-2

主持人：Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina

Session 6: Locoregional Therapy（局部区域治疗）

地点：Room 221ABC

主持人：Mylin Torres, Winshop Cancer Institute of Emory University

Session 8: Novel HER2 Therapeutics（新型HER2治疗）

地点：Stars at Night 1-2

主持人：Ian Krop, Yale School of Medicine

Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies（ctDNA用于微小残留病检测、肿瘤进化和新技术）

地点：Stars at Night 3-4

主持人：Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina

Session 15: Survivorship – Biomarker predictors and other survival-associated factors（生存-生物标志物预测和其他生存相关因素）

地点：Room 221ABC

主持人：Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri

Session 10: Addressing Racial Disparities in Breast Cancer Outcomes（探讨乳腺癌结局的种族差异）

地点：Hemisfair Ballroom 3

主持人：Yara Abdou, University of North Carolina School of Medicine

Session 11: Imaging to Guide Breast Cancer Treatment – Molecular Imaging and AI（影像学指导乳腺癌治疗——分子影像学和人工智能）

地点：Hemisfair Ballroom 1-2

主持人：David Mankoff, Perelman School of Medicine University of Pennsylvania

Session 12: Immunobiology Impact on Therapeutic Efficacy（免疫生物学对治疗效果的影响）

地点：Room 221ABC

主持人：Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut

Session 13: Molecular determinants of therapeutic response and resistance - Spotight on CDK 4/6i and ADCs （治疗反应和耐药的分子决定因素——聚焦CDK4/6i和ADCs）

地点：Stars at Night 1-2  

主持人：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Session 14: Brain Metastasis（脑转移）

地点：Stars at Night 3-4

主持人：William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois